



PATENT
ATTORNEY DOCKET NO.: 98-4
Customer No.: 26839

#18 C¹⁵
3-28-02
P. 7.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:
MELIEF, Cornelis, et al.

Serial No.: 09/316,935

Filed: May 22, 1999

For: CD40 BINDING MOLECULES AND CTL
PEPTIDES FOR TREATING TUMORS

Group Art Unit: 1632

Examiner: A. Beckerleg

AMENDMENT AND RESPONSE

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

RECEIVED
MAR 15 2002
TECH CENTER 1600/2639

RECEIVED
MAR 15 2002
TECH CENTER 1600/2639

In response to the Final Office Action dated October 10, 2001, Applicants request the Examiner's reconsideration and reexamination of the application, in view of the following amendments and remarks. The due date for the response has been extended to March 10, 2002, by a Petition for a two-month extension of time, including the appropriate fee. In the event that additional fees are due in connection with this response, please debit Deposit Account No. 20-0087.

Please amend the application as follows:

IN THE CLAIMS:

Please cancel claims 1-13 with no prejudice or disclaimer to the subject matter therein.

Please add the following new claims:

14. (new) A composition comprising an anti-CD40 antibody or a fragment thereof and a CTL activating peptide.
15. (new) The composition of claim 14, wherein the anti-CD40 antibody is human, humanized, chimeric or Deimmunised™.